The Expression of Bcl-XL, Bcl-XS and p27Kip1 in Topotecan-Induced Apoptosis in Hepatoblastoma HepG2 Cell Line

REFERENCES

• Herben V. M., ten Bokkel Huinink W. W., Beijnen J. H. Clinical pharmacokinetics of topotecan [J]. Clin. Pharmacokinet 1996; 31: 85–102
   PubMed Web of Science ®Google Scholar
• Iyer L., Ratain M. J. Clinical pharmacology of camptothecins [J]. Cancer Chemother. Pharmacol. 1998; 42: S31–43
   Web of Science ®Google Scholar
• Emerson D. L., Besterman J. M., Brown H. R.S., Evans M. G., Leitner P. P., Luzzio M. J., Shaffer J. E., Sternbach D. D., Uehling D, Vuong A. In vivo antitumor of two new seven-substituted water-soluble camptothecin analogues [J]. Cancer Res. 1995; 55(3)603–609
   PubMed Web of Science ®Google Scholar
• Hsiang Y. H., Liu L. F. Indentification of mammalian DNA topoisomerase ?as an intracellular target of the anticancer drug camptothecin [J]. Cancer Res. 1988; 48(7)1722–1729
   PubMed Web of Science ®Google Scholar
• Liu L. F. DNA topoisomerase poisons as antitumor agent [J]. Annu. Rev. Biochem. 1989; 58: 351–375
   PubMed Web of Science ®Google Scholar
• Downes C. S., Johnson R. T. DNA topoisomerases and DNA repair [J]. Bioessays 1988; 8(6)179–184
   PubMed Web of Science ®Google Scholar
• Roca J. The mechanisms of DNA topoisomerase [J]. Trends Biochem. Sci. 1995; 20(4)156–160
   PubMed Web of Science ®Google Scholar
• Wang J. C. DNA topoisomerase [J]. Annu. Rev. Biochem. 1996; 65: 635–692
   PubMed Web of Science ®Google Scholar
• Pommier Y., Leteurtre F., Fesen M. R., Fujimori A., Bertrand R., Solary E., Kohlhagen G., Kohn K. W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitor [J]. Cancer Investig. 1994; 12(5)530–542
   PubMed Web of Science ®Google Scholar
• Liu L. F., Duann P, Lin C. T., D'Arpa P, Wu J. Mechanism of action of camptothecin [J]. Ann. NY Acad. Sci. 1996; 803: 44–49
   PubMed Web of Science ®Google Scholar
• Uckun F. M., Stewart C. F., Reaman G, Chelstrom L. M., Jin J, Chandan-Langlie M, Waddick K. G., White J, Evans W. E. In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells [J]. Blood 1995; 85(10)2817–2828
   PubMed Web of Science ®Google Scholar
• Fu Q., Kim S. W., Chen H. X., Grill S., Cheng Y. C. Degradation of topoisomerase I induced by topoisomerase I inhibitors is dependent on inhibitor structure but independent of cell death [J]. Molecular Pharmacology 1999; 55(4)677–683
   PubMed Web of Science ®Google Scholar
• Keshelava N., Groshen S., Reynolds C. P. Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines [J]. Cancer Chemother. Pharmacol. 2000; 45(1)1–8
   PubMed Web of Science ®Google Scholar
• Silber R., Degar B., Costin D., Newcomb E. W., Mani M., Rosenberg C. R., Morse L., Drygas J. C., Canellakis Z. N., Potmesil M. Chemosensitivity of lymphocytes from patients with B-cell chrsonic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs [J]. Blood 1994; 84(10)3440–3446
   PubMed Web of Science ®Google Scholar
• Mitsui I., Kumazawa E., Hirota Y., Aonuma M., Sugimori M., Ohsuki S., Uoto K., Ejima A., Terasawa H., Sato K. A new water-soluble camptothecin derivative Dx-8951f exhibits potent antitumor activity against human tumors in vitro and in vivo [J]. Jpn J Cancer Res 1995; 86(8)776–782
   PubMedGoogle Scholar
• Plumb J. A., Milroy R., Kaye S. B. Effects of the PH dependence of 3-(4,5-dimethyl-2-yl)-2,5-diphenyl-tetrazolium-bromide-formazan adsorption on chemosensitivity determined by a novel tetrazolium-based assay [J]. Cancer Res. 1989; 49(16)4435–4440
   PubMed Web of Science ®Google Scholar
• Takehara T., Liu X., Fujimoto J., Friedman S. L., Takahashi H. Expression and role of Bcl-xL in human hepatocellular carcinomas [J]. Hepatology. 2001; 34(1)55–61
   PubMed Web of Science ®Google Scholar
• Emanuele S., Calvaruso G., Lauricella M., Giuliano M., Bellavia G., D'Anneo A., Vento R., Tesoriere G. Apoptosis induced in hepatoblastoma HepG2 cells by the proteasome inhibitor MG132 is associated with hydrogen peroxide production, expression of Bcl-XS and activation of caspase-3 [J]. Int. J. Oncol. 2002; 21(4)857–65
   PubMed Web of Science ®Google Scholar
• Kim H., Rafiuddin-Shah M., Tu H. C., Jeffers J. R., Zambetti G. P., Hsieh J. J., Cheng E. H. Hierarchical regulation of mitochondrion-dependent apoptosis by BCL-2 subfamilies [J]. Nat. Cell. Biol. 2006; 8(12)1348–58
   PubMed Web of Science ®Google Scholar
• Lazou A., Iliodromitis E. K., Cieslak D., Voskarides K., Mousikos S., Bofilis E., Kremastinos D. T. Ischemic but not mechanical preconditioning attenuates ischemia/reperfusion induced myocardial apoptosis in anaesthetized rabbits: The role of Bcl-2 family proteins and ERK1/2 [J]. Apoptosis. 2006; 11(12)2195–204
   PubMed Web of Science ®Google Scholar
• Luo D., Cheng S. C., Xie H., Xie Y. Effects of Bcl-2 and Bcl-XL protein levels on chemoresistance of hepatoblastoma HepG2 cell line [J]. Biochem. Cell. Biol. 2000; 78(2)119–26
   PubMed Web of Science ®Google Scholar
• Li W., Sanki A., Karim R. Z., Thompson J. F., Soon Lee C., Zhuang L., McCarthy S. W., Scolyer R. A. The role of cell cycle regulatory proteins in the pathogenesis of melanoma [J]. Pathology. 2006; 38(4)287–301
   PubMed Web of Science ®Google Scholar